论文部分内容阅读
化疗是肿瘤治疗的重要手段之一。化疗药物在杀灭肿瘤细胞的同时不可避免地杀伤部分人体免疫功能细胞，尤其是淋巴细胞、为此作者采用海口生物医学工程应用研究所研制的肝细胞刺激因子（以下称HCSF）以增强税体免疫力，从而达到抗肿瘤作用。选择80例经病理证实为肺癌Ⅲ·Ⅳ期患者，随机分为实验组37例，对照组33例。免疫指标为了淋巴细胞亚群，NK细胞活性。结果：实验组中NK细胞活性，CD25给药后2周和6周与给药前相比，P＜0．01，CD4P＜0．05、CD4／CD5给药后6周与给药前相比P＜0．05；对照组只有CD4，在化疗第2周有所增加。实验组与对照组从增加免疫功能的程度和趋势来看、以NK细胞和淋巴细胞亚群做指标，实验组有增加趋势，而对照组除CD4外其余均呈减少趋势，本组结果表明HCSF主要具有调节病人外周血NK细胞，CD4和CD25的活性，可以认为HCSF是一种值得重视和进一步研究的生物反应调节剂。
Chemotherapy is one of the important means for cancer treatment. The chemotherapeutic drugs inevitably kill and injure part of human immune cells, especially lymphocytes, while killing tumor cells. To this end, the authors used the hepatocyte stimulating factor (hereinafter referred to as HCSF) developed by Haikou Biomedical Engineering Application Research Institute to enhance the tax body. Immunity to achieve anti-tumor effects. Eighty patients with pathologically confirmed lung cancer stage III and IV were randomly divided into experimental group (37 cases) and control group (33 cases). Immune index for lymphocyte subsets, NK cell activity. Results: The activity of NK cells in the experimental group, 2 weeks and 6 weeks after the administration of CD25 compared with before administration, P<0.01, CD4P<0.05, 6 weeks after the administration of CD4/CD5 and before administration The ratio was P<0.05; the control group had only CD4, which increased during the second week of chemotherapy. In the experimental group and the control group, NK cells and lymphocyte subsets were used as indices to increase the degree of immunological function and the trend was observed in the experimental group, while the control group showed a decreasing trend except for CD4. The results in this group showed that HCSF It mainly regulates the activity of NK cells, CD4 and CD25 in peripheral blood of patients. It can be considered that HCSF is a biological response modifier worthy of attention and further study.